Clinical efficacy of Linaclotide in treatment of mental disease with constipation

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200063143

Enrollment

Unknown

Registered

2022-08-31

Start date

2022-09-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Constipation

Interventions

Linaclotide Group:Linaclotide

PEG-4000 Group:Polyethylene glycol 4000 powder

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. All patients met the diagnostic criteria for various mental diseases; 2. All patients met the diagnostic criteria for constipation; 3. Severe constipation symptoms affect patients' quality of life.

Exclusion criteria

Exclusion criteria: 1. Known or suspected intestinal obstruction; 2. Those who are known to be allergic to the drug ingredients used in this study or have contraindications; 3. Patients with severe heart, liver, lung, kidney diseases and electrolyte disorders; 4. Previous history of abdominal surgery; 5. Pregnant or lactating patients; 6. Patients aged 80 years; 7. Patients diagnosed with constipation-type irritable bowel syndrome (IBS-C).

Design outcomes

Primary

Measure	Time frame
Frequency of spontaneous defecation per week after treatment;	—

Secondary

Measure	Time frame
Wexner Constipation Scoring Scale;Constipation Patients Quality of Life Scale (PAC-QOL) Score;Bristol Stool Form Scale Score;	—

Countries

China

Contacts

Public ContactWen Jing

wenjingdudu@126.com+86 15611065923

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026